Eva Jack | Chief Business Officer |
Anna Protopapas | CEO |
Tim Lowinger | Chief Scientific Officer |
Dave Spellman | CFO |
Jonathan Chang | Leerink Partners |
Jessica Fye | JP Morgan |
Debjit Chattopadhyay | H.C. Wainwright |
Boris Peaker | Cowen |
Good morning and welcome to the Mersana Therapeutics’ Second Quarter 2018 Financial Results Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the call over to the Mersana team. Please proceed.